Assessment of multiplex Onchocerca volvulus peptide ELISA in non-endemic tropical regions.
Diagnostics
Multiplex ELISA
Onchocerca volvulus
Peptide serology
Journal
Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774
Informations de publication
Date de publication:
29 Nov 2019
29 Nov 2019
Historique:
received:
30
08
2019
accepted:
23
11
2019
entrez:
1
12
2019
pubmed:
1
12
2019
medline:
29
4
2020
Statut:
epublish
Résumé
Currently, serodiagnosis of infection with the helminth parasite Onchocerca volvulus is limited to the Ov-16 IgG4 test, a test that has limited sensitivity and suboptimal specificity. In previous studies, we identified several linear epitopes that have the potential to supplement the diagnostic toolbox for onchocerciasis. In this study three peptides, bearing in total six linear epitopes were transferred to a multiplex ELISA platform. This multiplex ELISA was used to assess the clinical utility of the peptide serology markers by analyzing sample sets from both O. volvulus endemic and non-endemic regions. The multiplex platform was shown to be reproducible and data obtained on the multiplex platform were comparable to the singleplex ELISA data. The clinical utility assessment showed that in a population of school-aged children from western Kenya, a virtually O. volvulus-free area, significant cross-reactivity with an as-yet to be determined immunogen was detected. The observations made in this study invalidate the usefulness of the peptide serology markers for onchocerciasis detection. We discuss what could be the origin of this unexpected serological response, but also highlight the need for better characterized biobanks for biomarker discovery activities.
Sections du résumé
BACKGROUND
BACKGROUND
Currently, serodiagnosis of infection with the helminth parasite Onchocerca volvulus is limited to the Ov-16 IgG4 test, a test that has limited sensitivity and suboptimal specificity. In previous studies, we identified several linear epitopes that have the potential to supplement the diagnostic toolbox for onchocerciasis.
METHODS
METHODS
In this study three peptides, bearing in total six linear epitopes were transferred to a multiplex ELISA platform. This multiplex ELISA was used to assess the clinical utility of the peptide serology markers by analyzing sample sets from both O. volvulus endemic and non-endemic regions.
RESULTS
RESULTS
The multiplex platform was shown to be reproducible and data obtained on the multiplex platform were comparable to the singleplex ELISA data. The clinical utility assessment showed that in a population of school-aged children from western Kenya, a virtually O. volvulus-free area, significant cross-reactivity with an as-yet to be determined immunogen was detected.
CONCLUSIONS
CONCLUSIONS
The observations made in this study invalidate the usefulness of the peptide serology markers for onchocerciasis detection. We discuss what could be the origin of this unexpected serological response, but also highlight the need for better characterized biobanks for biomarker discovery activities.
Identifiants
pubmed: 31783767
doi: 10.1186/s13071-019-3824-x
pii: 10.1186/s13071-019-3824-x
pmc: PMC6884800
doi:
Substances chimiques
Antigens, Helminth
0
Epitopes
0
Peptides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
570Références
World Health Organ Tech Rep Ser. 1995;852:1-104
pubmed: 7541171
Parasit Vectors. 2017 Jan 7;10(1):15
pubmed: 28061905
Am J Trop Med Hyg. 1989 Oct;41(4):467-71
pubmed: 2802024
J Helminthol. 1962;36:375-449
pubmed: 13982707
PLoS Negl Trop Dis. 2013 Jul 11;7(7):e2288
pubmed: 23875033
Bull Entomol Res. 1947 Mar;37(4):619-28
pubmed: 20287805
PLoS One. 2013 Jul 23;8(7):e69231
pubmed: 23935960
Clin Vaccine Immunol. 2015 Aug;22(8):896-901
pubmed: 26018537
Asian Pac J Trop Med. 2016 Mar;9(3):205-10
pubmed: 26972389
Cancer Res. 2006 Nov 15;66(22):10795-804
pubmed: 17108116
Ann Trop Med Parasitol. 1964 Jun;58:153-8
pubmed: 14183100
Mem Inst Oswaldo Cruz. 2014 Jul;109(4):506-8
pubmed: 25075790
Acta Trop. 2011 Sep;120 Suppl 1:S109-20
pubmed: 20152790
Parasitol Res. 2019 Jul;118(7):2263-2270
pubmed: 31089811
Lancet. 2014 May 24;383(9931):1803
pubmed: 24856022
PLoS Negl Trop Dis. 2017 Jan 23;11(1):e0005314
pubmed: 28114304
Cutis. 2003 Oct;72(4):297-302; quiz 296
pubmed: 14604081
Lab Chip. 2015 Jun 21;15(12):2538-58
pubmed: 25953427
Parasit Vectors. 2016 May 31;9(1):311
pubmed: 27245442
Parasit Vectors. 2015 Oct 24;8:560
pubmed: 26496983
Bull World Health Organ. 1958;19(1):75-107
pubmed: 13585062
PLoS Negl Trop Dis. 2018 Feb 9;12(2):e0006226
pubmed: 29425201
PLoS Negl Trop Dis. 2017 Jan 26;11(1):e0005330
pubmed: 28125577
Res Rep Trop Med. 2018 Jan 18;9:9-24
pubmed: 30050351
Clin Microbiol Rev. 1998 Apr;11(2):366-81
pubmed: 9564568
PLoS Negl Trop Dis. 2016 Apr 01;10(4):e0004596
pubmed: 27035146
Ann Trop Med Parasitol. 2005 Jun;99(4):383-93
pubmed: 15949186
Bull World Health Organ. 1967;37(2):195-212
pubmed: 5303323
Trends Parasitol. 2015 Nov;31(11):571-582
pubmed: 26458784
Am J Trop Med Hyg. 2018 Mar;98(3):779-785
pubmed: 29313477
Afr J Infect Dis. 2010;4(1):7-14
pubmed: 23878696
Parasit Vectors. 2019 Jan 28;12(1):63
pubmed: 30691520
Parasite Immunol. 2018 Nov;40(11):e12587
pubmed: 30188578
Comb Chem High Throughput Screen. 2001 Feb;4(1):75-110
pubmed: 11281827
J Clin Invest. 2008 Apr;118(4):1311-21
pubmed: 18382743
Trends Parasitol. 2012 Jul;28(7):280-8
pubmed: 22633470